Journal
CURRENT OPINION IN MICROBIOLOGY
Volume 14, Issue 5, Pages 570-576Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.mib.2011.07.022
Keywords
-
Categories
Funding
- European Commission [LSHP-CT-2005-018923, 260872]
Ask authors/readers for more resources
Tuberculosis (TB) remains a major global health concern whose control has been exacerbated by HIV and the emergence of multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains of Mycobacterium tuberculosis. The demand for new and faster acting TB drugs is thus greater than ever. In the past decade intensive efforts have been made to discover new leads for TB drug development using both target-based and cell-based approaches. Here, we describe the most promising anti-tubercular drug candidates that are in clinical development and introduce some nitro-aromatic compounds that inhibit a new target, DprE1, an essential enzyme involved in a crucial step in mycobacterial cell wall biosynthesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available